Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea (OSA), a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep. The data showed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies.  Also Read: Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy. AHI records the number of times a person’s breathing shows a restricted or complete block of airflow per hour of ...